China’s First 2024 Biotech Acquisition by DCTY
DCTY's acquisition marks a milestone in China's biotech scene, introducing advanced TCR and CAR T-cell therapies domestically.
- Latest
- Trending
DCTY's acquisition marks a milestone in China's biotech scene, introducing advanced TCR and CAR T-cell therapies domestically.
AbCellera Biologics Inc. progresses with their TCE platform and strategic partnerships, aiming for CTA submissions in Q2 2025.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.